The Effect of SERM/CB

Victoria Gorberg, Peter McCaffery, Sharon Anavi-Goffer

Abstract readComparative Study

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Victoria GorbergInstitute of Medical Sciences, University of Aberdeen, Aberdeen AB24 2ZD, UK.

Peter McCafferyInstitute of Medical Sciences, University of Aberdeen, Aberdeen AB24 2ZD, UK.ORCID 0000-0002-5956-3997

Sharon Anavi-GofferInstitute of Medical Sciences, University of Aberdeen, Aberdeen AB24 2ZD, UK.

Funding

Tourette Association of America A Role for Cannabinoid CB2 Receptor in Tourette Syndrome: Characterizing Novel Inhibitors for the treatment of Tourette Syndrome

6 · The paper itself

Abstract

Tourette syndrome (TS) is a neurodevelopmental disorder, with a male-to-female ratio of approximately 3:1, characterised by involuntary tics, frequently comorbid with conditions such as obsessive-compulsive disorder (OCD). Some patients exhibit limited responsiveness to standard medications, necessitating alternative therapeutic strategies. Clomiphene, a selective oestrogen receptor modulator (SERM), emerged as a potential candidate. However, raloxifene and bazedoxifene, which exhibit distinct chemical structures from clomiphene, present dual modulation not only as oestrogen receptor modulators but also as inverse agonists of the cannabinoid CB

Indexed as

Obsessive-Compulsive DisorderReceptor, Cannabinoid, CB2Selective Estrogen Receptor ModulatorsTourette SyndromeAnimalsClomipheneDrug Inverse AgonismFemaleGroomingIndolesLocomotionMaleMiceMice, Inbred C57BLRaloxifene HydrochlorideSex FactorsbazedoxifeneClomipheneIndolesRaloxifene HydrochlorideReceptor, Cannabinoid, CB2Selective Estrogen Receptor ModulatorsbazedoxifeneCB1 receptorCB2 receptorclomipheneendocannabinoid systemEvistaobsessive–compulsive disorder (OCD)raloxifeneselective oestrogen receptor modulator (SERM)Tic disorderTourette syndrome (TS)

Identifiers

PMID41683609

DOI10.3390/ijms27031181

PMCPMC12898493

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.